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Abstract
Objectives To study the ratio of ablation zone volume to applied energy in computed tomography (CT)-guided radiofrequency
ablation (RFA) and microwave ablation (MWA) in patients with hepatocellular carcinoma (HCC) in a cirrhotic liver and in
patients with colorectal liver metastasis (CRLM).
Methods In total, 90 liver tumors, 45 HCCs in a cirrhotic liver and 45 CRLMs were treated with RFA or with one of two MWA
devices (MWA_A and MWA_B), resulting in 15 procedures for each tumor type, per device. Device settings were recorded and
the applied energy was calculated. Ablation volumes were segmented on the contrast-enhanced CT scans obtained 1 week after
the procedure. The ratio of ablation zone volume in milliliters to applied energy in kilojoules was determined for each procedure
and compared between HCC (RHCC) and CRLM (RCRLM), stratified according to ablation device.
Results With RFA, RHCC and RCRLM were 0.22 mL/kJ (0.14–0.45 mL/kJ) and 0.15 mL/kJ (0.14–0.22 mL/kJ; p = 0.110),
respectively. With MWA_A, RHCC was 0.81 (0.61–1.07 mL/kJ) and RCRLM was 0.43 (0.35–0.61 mL/kJ; p = 0.001). With
MWA_B, RHCC was 0.67 (0.41–0.85 mL/kJ) and RCRLM was 0.43 (0.35–0.61 mL/kJ; p = 0.040).
Conclusions With RFA, there was no significant difference in energy deposition ratio between tumor types.With bothMWAdevices,
the ratios were higher for HCCs. Tailoring microwave ablation device protocols to tumor type might prevent incomplete ablations.
Key Points
• HCCs and CRLMs respond differently to microwave ablation
• For MWA, CRLMs required more energy to achieve a similar ablation volume
• Tailoring ablation protocols to tumor type might prevent incomplete ablations
Keywords Ablation techniques . Carcinoma, Hepatocellular . Radiology, Interventional . Multidetector computed tomography .
Liver diseases
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For over 15 years, hepatic malignancies have been treated
successfully with radiofrequency ablation (RFA) and micro-
wave ablation (MWA) [1–3]. Themost important drawback of
thermoablative therapies is recurrence of disease at the
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ablation site, with reported recurrence rates of 5.0–32.1% [2,
4–6]. Independent risk factors for incomplete ablation
and ablation site recurrence are larger tumor size, prox-
imity of peritumoral vessels, improper placement of the
ablation needle, and insufficient safety margin around
the liver tumor [7–9].
To ensure complete coverage of the liver tumor including a
safety margin, the creation of a predictable ablation zone is
crucial. Ablation protocols provided by manufacturers are
mostly based on ex vivo ablation of nonperfused, nondiseased
livers from animals. It can be expected that the resulting abla-
tion zones in these livers would differ significantly from abla-
tion zones after in vivo treatment of diseased livers in humans.
Studies investigating the reproducibility and reliability of RFA
andMWA in different tumor types and in abnormal underlying
liver parenchyma (cirrhosis) in humans are lacking.
We designed this study to evaluate the ablation zone vol-
ume after RFA and MWA. The aims of this study were: (1) to
find the relationship between the amount of applied energy
and the resulting ablation zone volume for RFA and MWA
devices during in vivo ablation in patients, and (2) to investi-
gate whether the ratio of ablation zone volume in milliliters to
applied energy in kilojoules [R(AZ:E)] differs between hepa-




The study was approved and the need for informed consent
was waived by the Institutional Review Board of the
University Medical Center Groningen (no. 2015/521). Data
were processed anonymously. Thermoablation of liver tumors
was introduced in 2000 in our hospital, ultrasound-guided
during open surgery and CT-guided during percutaneous pro-
cedures. Over 600 ablation procedures (approximately 70%
percutaneously) have been performed for various types of
liver tumors in our hospital. In the present study we analyzed
only patients who underwent percutaneous CT-guided
thermoablation for either CRLM or HCC in the period from
March 2009 to January 2016. All patients were discussed in a
tumor board meeting in which the decision for percutaneous
thermoablation was made.
Patients were included in this study if they were treated for
HCC in a cirrhotic liver or for CRLM. Patients were excluded
if: (1) there was overlap between the ablation zones of multi-
ple lesions, (2) the tumor had previously been treated with
ablation therapy, or (3) surgical clips caused beam hardening
on the control CT images preventing adequate segmentation
of the ablation zone. For each of the three ablation devices
used, 30 ablation treatments were included: 15 tumors in
patients consecutively treated for HCC, and 15 tumors in pa-
tients consecutively treated for CRLM. In this paper we ad-
here to the standard terminology and reporting criteria recom-
mended by Ahmed et al. [10].
Procedures
Procedures were performed by one of two surgeons (K. de J.
and E.S.) with 16 and 12 years of experience in liver ablation,
respectively, with the support of a radiologist. All procedures
were performed under general anesthesia. Procedural CT
scans and needle manipulations were performed during max-
imal expiration and after full elastic recoil of the thorax. This
situation was obtained when CO2 monitoring of the exhaled
breathing air in the respiratory tube revealed a completely flat
baseline. Thermoablation was performed with one of three
devices (see below), and manufacturers’ protocols were
followed. Device settings were recorded during the proce-
dures. Needle placement was performed based on the expect-
ed ablation zone size described by the manufacturer, consid-
ering a sufficient (>5 mm) safety margin around the tumor.
Larger lesions were treated by creating several partially over-
lapping ablation zones. After treatment of the tumor, the ab-
lation needle was removed while ablating the tract.
CT scan protocol
Control CT scans were acquired 1 week after the ablation
procedure on a 64-multidetector CT system (Somatom
Sensation 64; Siemens Medical, Erlangen, Germany). The
tube voltage was 120 kVp and the quality reference tube cur-
rent was 120 mAs. Scans were acquired prior to administra-
tion of intravenous contrast agent (110 mL of Iomeron 300;
Bracco Imaging), and in the arterial and portal venous phases,
and reconstructed with slice thicknesses of 2–5 mm, 0.75–
3 mm and 2 mm using a medium smooth B30f kernel.
Ablation systems
The RFA system consisted of a 480-kHz generator with a
maximum power output of 250 W (RF 3000 generator with
Leveen needles; Boston Scientific Corp., Natick, MA). The
diameters of the RFA needle electrodes with umbrella arrays
ranged from 2 to 5 cm. The diameter of the needle electrodes
was determined by the size of the tumor.
MWA system A consisted of a 2.45-GHz generator gener-
ating a maximum of 140 W with water-cooled needle elec-
trodes (Acculis Sulis VpMTA;Microsulis Medical, Denmead,
UK). MWA system B also used a 2.45-GHz frequency band,
generating a maximum of 100 W, with water-cooled needles
and thermal, field, and wavelength control to optimize the
predictability of the ablation zone (Emprint MWA
Generator; Covidien, Dublin, Ireland).
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Ablation protocols and applied energy
The manufacturer of the RFA system provided separate algo-
rithms for each of the various needle diameters, prescribing
the time and power settings to be applied during the proce-
dure. The power of the system was manually increased ac-
cording to this algorithm until roll-off was achieved. Roll-off
is defined as a steep rise in tissue impedance, and is an indi-
cation of a successful ablation cycle. For each tumor, two
complete ablation cycles were generated according to the
manufacturer’s algorithm. During the RFA procedure, the
time required to achieve roll-off and the roll-off indication
power were recorded for each ablation cycle. These measure-
ments were used to determine the area under the curve for time
and power, resulting in the amount of energy applied in each
ablation cycle. Next, the total amount of applied energy to
each tumor was determined by summing the applied energy
of all ablation cycles.
The manufacturers of MWA systems A and B provided
tables with specific power and time settings according to the
expected resulting ablation size. Appropriate settings were
chosen, and these were recorded during the procedures. The
power and time settings were used to determine the amount of
applied energy in each ablation cycle, and subsequently
summed per lesion to determine the total amount of energy
applied.
Ablation zone volumetry
Volumetry of the ablation zone was performed on the portal
venous phase acquisition with 2-mm slice reconstruction
using the semiautomatic Liver Lesion Segmentation tool
(MM Oncology package; syngo.via; Siemens Medical,
Erlangen, Germany). After initial manual measurement of
the cross section of the tumor, this tool automatically delineat-
ed the tumor, and this was subsequently verified for each slice
and, when necessary, corrected by two independent observers
(W.H. and A.S.). Interobserver reliability of volumetry was
expressed in terms of the intraclass correlation coefficient
(ICC). An ICC value larger than 0.90 was considered as high
agreement. In ten ablation volumes with a discrepancy in de-
lineation between the observers of more than 10%, agreement
in delineation between the ablation zone and perilesional en-
hancement was checked in a consensus meeting of the two
observers, and was subsequently obtained by consensus. For
the other ablation zones, the mean of the ablation zone vol-
umes obtained by the observers was used for statistical anal-
ysis. R(AZ:E) was determined by dividing the ablation zone
volume in milliliters by the amount of energy in kilojoules
applied in each procedure.
Tumor size was determined as the largest diameter on
contrast-enhanced transverse CT images acquired minutes be-
fore the ablation procedure. Tumor volume as a percentage of
the total ablation zone volume was calculated by dividing the
estimated tumor volume (based on diameter, assuming the
lesions were spherical) by the total ablation zone volume.
Ablations were considered incomplete when the control CT
scan acquired after 1 week revealed that the ablation zone did
not completely cover the tumor including a margin of at least
5 mm around the tumor in all directions. The potential for
tumors to show the heat-sink effect was categorized as ‘high’
or ‘low’ depending on the peritumoral vascularity. The poten-
tial was considered to be high if tumor-abutting vessels with a
diameter of ≥3 mm were present, as defined previously [8].
Statistical analysis
Patient age, lesion size, peritumoral vascularity, ablation time,
energy applied, number of ablation needle positions, ablation
zone volume, energy deposition ratio, tumor percentage in
ablation zone volume, and number of incomplete ablations
were compared between the three ablation devices and be-
tween tumor types stratified according to the ablation device.
R(AZ:E) was compared between tumor types using the Mann-
WhitneyU test. For each device, the R(AZ:E) of tumors with a
potentially high and low heat-sink effect were compared.
Potential correlations between peritumoral vascularity and tu-
mor type were evaluated using the chi-squared test. For RFA,
the effect of the size of the needle’s umbrella array onR(AZ:E)
was evaluated using Spearman’s rank test, and median array
diameters were compared between HCC and CRLM. The
R(AZ:E) of CRLMs were compared between those who did
and did not receive prior systemic therapy.
Parameters were tested for normality using the Shapiro-
Wilk test. The means and standard deviations (SD) of contin-
uous, normally distributed parameters were determined and
compared using one-way analysis of variance or the
independent-samples t test. The medians and interquartile
ranges (IQR) of non-normally distributed variables were de-
termined and tested for homogeneous non-normality and
compared using the Kruskal-Wallis test or the Mann-
Whitney U test. Dichotomous data were compared using
Fisher’s exact test. Differences with p values <0.05 were con-
sidered significant, and p values were not adjusted for multiple
comparisons. Statistical analyses were performed using IBM
SPSS Statistics version 23 (IBM Corporation, Armonk, NY).
Results
Patients and procedures
In total, 90 liver tumors in 78 patients were included in this
study. Of these 90 tumors, 45 in 35 patients (27 men, median
age 67 years, IQR 15 years) were HCCs with a mean diameter
of 25.0 mm (SD 9.6 mm), ranging from 6 to 55 mm, and 45 in
3230 Eur Radiol (2018) 28:3228–3236
43 patients (26 men, median age 64 years, IQR 12 years) were
CRLMs with a mean diameter of 22.5 mm (SD 10.6 mm),
ranging from 7 to 60 mm. In total, 14 tumors between 30 mm
and 40 mm in size, and four larger than 40 mmwere included.
These larger tumors were treated with thermoablation because
in these patients no other form of therapy was available.
Seventeen patients had received prior systemic chemotherapy,
with a mean of 1.1 years between chemotherapy and ablation.
None of the tumors had been treated with transarterial
(chemo)embolization.
All 90 tumors were treated in 80 sessions. In 14 tumors
(15.5%) the ablation was incomplete. The median ablation
zone volume for all tumors was 55.7 mL (IQR 55.9 mL).
The interobserver correlation for volumetry of the ablation
zone was high (ICC 0.994, 95% confidence interval 0.990–
0.996, p < 0.001).
Comparison of devices
Table 1 shows baseline patient and tumor variables for each
ablation device. In general, the median ablation time was lon-
ger with RFA than with MWA (TRFA = 48 min, TMWA_A = 14
min, TMWA_B = 20 min; p < 0.001). Also, the median applied
energy was higher with RFA (ERFA = 294.0 kJ, EMWA_A =
111.0 kJ, EMWA_B = 111.0 kJ; p = 0.001). Ablation zone vol-
umes, number of needle positions, tumor volume percentages
and numbers of incomplete ablations were approximately sim-
ilar for all devices. The ablated tumor volume as a percentage
of the total ablated volumewas remarkably low, with a median
value of 11.2% (IQR 5.1–23.1%). R(AZ:E) was lower with
RFA than with MWA (RRFA = 0.17, RMWA_A = 0.66, RMWA_B
= 0.46; p < 0.001). The ratios for MWA devices A and B were
not significantly different (p = 0.344).
With RFA, the needle array size was correlated with
R(AZ:E) with a Spearman’s correlation coefficient of −0.415
(p = 0.023; i.e. larger needle arrays result in a lower R(AZ:E).
The median needle array sizes were similar for HCC and
CRLM: 3.5 cm and 3.5 cm, respectively (p = 0.337).
Prior systemic therapy did not have a significant effect on
R(AZ:E) for any of the devices. With RFA, the median (IQR)
R(AZ:E) values of CRLMs in patients who did and did not
receive prior systemic therapy were 0.14 (0.10–0.20) and 0.18
(0.15–0.23; p = 0.083), respectively. With MWA_A, median
R(AZ:E) values were 0.34 (0.21–0.80) and 0.38 (0.34–0.56; p
= 0.713), and with MWA_B were 0.35 (0.17–0.75) and 0.43
(0.37–0.62; p = 0.391), respectively.
Comparison of HCC with CRLM
Table 2 shows the clinicopathological and procedural charac-
teristics separately for HCC and CRLM, stratified according
to the type of ablation device used. The tumor diameter, num-
ber of peritumoral vessels, needle positions and incomplete
ablations did not differ between the tumor types, for any of
the devices.
With RFA, R(AZ:E) did not differ significantly between
tumor types (RHCC = 0.22, RCRLM = 0.15; p = 0.110). With
both MWA devices, R(AZ:E) was higher for HCC than for
CRLM: MWA_A, RHCC = 0.81, RCRLM = 0.43 (p = 0.001),
and MWA_B, RHCC = 0.67, RCRLM = 0.43 (p = 0.040). Thus,
MWA generates larger ablation zone volumes per kilojoule in
HCC than in CRLM. Figure 1 shows the applied energy in
Table 1 Patient and tumor
characteristics RFA MWA_A MWA_B p value
R(AZ:E) (mL/kJ) 0.17 (0.14–0.26) 0.66 (0.37–0.86) 0.46 (0.37–0.77) <0.001
Number of lesions 30 30 30
Patients 24 28 26
Gender (male/female) 19/5 19/9 15/11 0.072
Age (years) 64.3 (7.7) 66.4 (11.2) 65.8 (12.1) 0.741
Lesion diameter (mm) 21.3 (7.2) 25.8 (12.6) 24.1 (9.8) 0.380
Ablation time (min) 48 (21–75) 14 (4–23) 20 (11–29) <0.001
Applied energy (kJ) 294.0 (83.5–504.5) 111.0 (38.1–183.9) 111.0 (52.9–169.2) 0.001
Ablation volume (mL) 49.4 (23.8–75.2) 63.9 (35.9–92.0) 69.0 (25.6–112.4) 0.364
Needle positions (n) 4 (1) 4 (5) 3.5 (2) 0.535
Tumor percent of total ablation
zone volume
9.4 (3.4–15.4) 14.0 (3.0–25.0) 11.5 (1.5–21.5) 0.516
Previous systemic therapy 7 5 5 0.611
Incomplete ablations after
1 week follow-up (n)
4 7 3 0.118
Normally distributed data are presented as means (SD) and non-normally distributed data as medians (Q1–Q3)
R(AZ:E) ratio of ablation zone volume in milliliters to applied energy in kilojoules
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relation to the ablation zone volume as scatter plots grouped
by generator, and grouped by tumor type according to
generator.
Example images of an HCC and a CRLM prior to ablation
with MWA_B and of the resulting ablation zone volumes are
shown in Fig. 2. In both these cases, 96 kJ of energy was
applied, yet the resulting ablation zone volume in the HCC
was more than twice that in the CRLM.
There were no significant correlations between heat-sink
and tumor type for RFA, MWA_A and MWA_B (p = 0.682,
p = 0.466, p = 0.245, respectively). There were no significant
differences in R(AZ:E) between ‘high’ and ‘low’ heat-sink
tumors with RFA (Rhigh = 0.20, IQR 0.15–0.24, RLow =
0.16, IQR 0.13–0.28, p = 0.743). With MWA_A, R(AZ:E)
was significantly lower for ‘high’ heat-sink tumors (Rhigh =
0.39, IQR 0.33–0.76, Rlow = 0.83, IQR 0.47–1.06, p = 0.016),
but with MWA_B there was no significant difference in
R(AZ:E) between ‘high’ and ‘low’ heat-sink tumors (Rhigh =
0.55, IQR 0.40–0.89, Rlow = 0.46, IQR 0.37–0.65, p = 0.422).
Thus, the ablation zones created by MWA_Awere smaller in
the presence of peritumoral vessels ≥3 mm than those created
by the other two devices which seemed to be less influenced
by the presence of such vessels.
Discussion
The purpose of this study was to evaluate the relationship
between the amount of applied energy and the resulting abla-
tion zone volume in liver tumors for RFA and MWA devices.
To this end R(AZ:E) was calculated for each procedure. With
RFA, R(AZ:E) was similar in HCC and in CRLM. With both
MWA devices, R(AZ:E) was higher in HCC than in CRLM
(about twofold higher with MWA_A and about 50% higher
with MWA_B).
The HCCs selected for this study were all in patients with a
cirrhotic liver, whereas the patients with CRLMs had an oth-
erwise healthy liver. The difference in the treatment effects
observed between the two tumor types may have been the
result of differences in tumor characteristics and in the sur-
rounding liver parenchyma associated with the underlying
liver disease. Probably, all of these factors contributed to the
differences measured. The differences measured may also be
associated with underlying differences in electrical properties
(relative permittivity and electrical conductivity) and/or ther-
mal properties (thermal conductivity, specific heat capacity,
density and nominal blood perfusion rate).
Deshazer et al. recently investigated the effect of these
properties on the resulting MWA zone using a two-
compartment (tumor and surrounding liver parenchyma) com-
puter model [11]. They concluded that the ablation zone vol-
ume was minimally affected by the tissue characteristics ; the
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were differences in thermal conductivity and hepatic perfusion
of the surrounding liver parenchyma. In our study, most of the
ablated tissue volume was liver parenchyma and less than
20% consisted of tumor. This seemingly low ratio can be
explained by the example that the volume of a spherical 10-
mm tumor would only be 12.5% of the total ablation zone
volume if a perfect 5-mm safety margin was created around
the tumor. This low tumor percentage supports the findings of
Deshazer et al. indicating that the main factor influencing the
difference in treatment effects between the tumor types is a
difference in tissue characteristics between normal and cir-
rhotic liver parenchyma.
Another variable could be the difference in total liver blood
flow between normal livers (with CRLM) and cirrhotic livers
(with HCC). Although in some studies an increase in total
liver blood flow has been found in cirrhotic livers [12], inmost
studies cirrhotic liver parenchyma has been found to be less
perfused than normal liver parenchyma [13, 14]. According to
the model, a decrease in liver perfusion from 18 kg m−1s−1
(normal) to 11 kg m−1s−1 (cirrhotic) would result in an in-
crease in ablation zone volume of 37% [11]. This corresponds
approximately to our results with the MWA devices.
Differences in energy deposition between HCC and CRLM
could also be caused by the pseudocapsule of HCCs. This
pseudocapsule has been considered as a reason for the occur-
rence of a hypothetical Boven effect^, that is higher tempera-
tures inside the tumor, but lower temperatures outside because
of the low thermal conductivity of the capsule. With RFA, it
remains to be seen how much heat this capsule actually helps
to contain. With MWA, this oven effect is less likely to occur,
as MWA does not rely on thermal conductivity in contrast to




























































































Fig. 1 Regression analysis of the relationships between applied energy
and (a) ablation zone volume for the three devices, (b) ablation zone
volume obtained with the RFA device (Boston Scientific Corp.)
grouped by tumor type, (c) ablation zone volume obtained with the
MWA device A (Microsulis Medical) grouped by tumor type, and (d)
ablation zone volume obtained with the MWA device B (Covidien)
grouped by tumor type (CRLM colorectal liver metastasis, HCC hepato-
cellular carcinoma)
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MWA and RFA in HCC can be found in a review by Poggi
et al. [15]. Since the observed difference in ablative effects
between HCC and CRLM in this study occurred only with
MWA, it is not likely that the oven effect was a significant
contributor.
With RFA, the size of the umbrella array significantly af-
fected the ratio of energy deposition. Larger arrays resulted in
lower R(AZ:E). This might have been because smaller needle
arrays have a better energy deposition, or because larger arrays
have relatively more overlap when performing ablation at
multiple locations, and thereby lose energy deposition effi-
ciency. For both tumor types the median RFA antenna size
was similar, so it is unlikely that this contributes to how tumor
type affects the ratio of energy deposition.
To our knowledge, there is only one clinical study compar-
ing the correlation between applied energy and ablation zone
size with MWA in HCCs and CRLMs [16]. That study gen-
erated conflicting results: for shorter ablation times they found
no difference in effect, and for longer ablation times they
found smaller ablation diameters in HCC than in metastases.
They did not, however, measure the volume of the ablation
zone, but only diameters. These were all procedures with a
single insertion and energy delivery. No overlapping ablations
were included, whereas most of the procedures in this study
were performed with overlapping ablations, which might be a
reason for the observed differences in outcome.
Lu et al. investigated the effect of the presence of a flow
heat-sink and found that the presence of large (>3 mm)
peritumoral vessels resulted in a higher ablation site malignan-
cy recurrence rate after RFA in liver tumors [8]. The presence
of such a heat-sink can be expected to affect the amount of
energy required to achieve a certain ablation volume. In our
Fig. 2 Left Preprocedural portal venous phase contrast enhanced CT
images of HCC in segment 6 (top) and CRLM in segment 4 (bottom) in
two patients who had not received systemic therapy or transarterial
(chemo)embolization. Using MWA device B, 96 kJ (100 W for
8:00 min × 2) and 96 kJ (100 W for 6:00 min, 100 W for 10:00 min)
were applied to the HCC and CRLM, respectively, with 16 mm and
14 mm between the two positions of the ablation center of the antenna,
so overlap was approximately similar. Right Resulting ablation zones
after segmentation on the 1-week follow-up portal venous phase
contrast-enhanced CT images using the MM Oncology package (syngo.-
via; Siemens, Erlangen, Germany), with ablation zone volumes of 96 mL
and 39 mL, resulting in energy deposition ratios of 1.00 mL/kJ and 0.41
mL/kJ for HCC and CRLM, respectively. After 6 months of follow-up,
the HCC showed no sign of recurrence, whereas a PETscan of the CRLM
showed activity at the dorsal side of the ablation zone, for which re-
ablation was performed
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study, this effect was demonstrated with MWA device A
which produced a lower R(AZ:E) in the tumors with
peritumoral vascularity than in the tumors without peritumoral
vascularity. In the RFA and MWA_B groups there was no
difference in R(AZ:E) between these types of tumor.
MWA_B utilizes thermal, field, and wavelength control to
produce spherical ablation zones, which might have contrib-
uted to the apparent insensitivity to the presence of a heat-sink
[17]. The fact that no heat-sink effects were observed in the
RFA group was somewhat unexpected and may have been
because only 8 of 30 tumors in that group were classified as
potentially ‘high’ heat-sink tumors.
Although both MWA devices operated in the 2.45 GHz
frequency range, their level of power output differed:
MWA_A generated more power than MWA_B. It is unclear
how much of this power was actually transferred into the
tissue because this is also affected by the energy reflected by
the cable and antenna. However, with MWA_A, the trans-
ferred power was probably higher and the duration was cer-
tainly shorter than with MWA_B. Studies investigating the
effect of differences in level of power output have generally
compared 915 MHz and 2.45 GHz devices [18, 19]. It is
therefore unclear how this might have affected the observed
differences between the two MWA devices.
There were some limitations to this study. Often a round-
ness index is used to quantify the quality of the ablation prop-
erties of a system [20]. This is because spherical ablation
zones are easier to predict and can potentially cover a tumor
better than ovoid ablation zones. In this study, however, 95%
of the tumors were treated at multiple needle positions which
meant that a roundness index of the entire ablation zone vol-
ume would not have been an accurate measure. This also
means that the amount of overlap could have contributed to
differences in the volume–energy relationship, because the
electrical and thermal properties of tissues change after abla-
tion. We were not able to determine the amount of overlap in
the procedures nor to compensate for this. Despite this, mean
lesion diameter, the number of needle positions, and the ab-
lated tumor volume expressed as a percentage of the total
volume were not different for the three devices or between
tumor types for the MWA devices. Therefore, it is not likely
that the amount of overlap was any different between these
groups either. Additionally, the nongeometric configuration of
the ablation zones was taken into account by a precise volume
evaluation of the ablation zone.
Finally, histology of adjacent liver parenchyma was not
performed, since it is not clinical practice to perform biopsies,
either of the tumor or of the liver, because diagnosis of both is
mainly determined based on the medical history of the patient,
laboratory results and radiological imaging.
In conclusion, with the MWA devices we found a differ-
ence in the ablation zone volume per kilojoule of energy ap-
plied between tumor types. Because HCCs require less energy
to achieve a certain ablation volume, CRLMs must be treated
by creating multiple ablations with plenty of overlap, or at a
relatively high power level or for a longer time. These data
clearly demonstrate that the manufacturers’ algorithms based
solely on power level and duration of application need to be
adapted to the type of tumor in its specific environment.
Therefore, it is critical to verify the dimensions of the ablation
zone early after the procedure using contrast-enhanced CT or
preferably contrast-enhanced magnetic resonance imaging.
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